APAC IPOs & Placements, Aequitas Research

Akshat Shah

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Symbiotec Pharmalab / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/symbiotec-pharmalab-ltd" target="_blank" data-smartkarma-citation="entities:46311:1" rel="noopener">Symbiotec Pharmalab Ltd (971073Z IN)</a> is looking to raise about US$244m in its upcoming India IPO. The deal will be run by Avendus, JM Fin, Nomura and Motilal Oswal.</li>
<li>SPL is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms-organic chemistry, biotechnology and complex injectables.</li>
<li>According to the Frost &amp; Sullivan report, SPL had a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients in volume terms in FY25.</li>
</ul>



Symbiotec Pharmalab Ltd (971073Z IN) is looking to raise about US$244m in its upcoming India IPO. The deal will be run by Avendus, JM Fin, Nomura and Motilal Oswal.
SPL is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms-organic chemistry, biotechnology and complex injectables.
According to the Frost &amp; Sullivan report, SPL had a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients in volume terms in FY25.


Aequitas: Symbiotec Pharmalab Ltd Pre-IPO Tearsheet